Rankings
▼
Calendar
CTMX Q1 2022 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$846M
Q1 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$9M
-43.4% YoY
Gross Profit
$9M
100.0% margin
Operating Income
-$32M
-354.7% margin
Net Income
-$32M
-353.8% margin
EPS (Diluted)
$-0.36
QoQ Revenue Growth
-54.2%
Cash Flow
Operating Cash Flow
-$41M
Free Cash Flow
-$42M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$297M
Total Liabilities
$229M
Stockholders' Equity
$68M
Cash & Equivalents
$163M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$9M
$16M
-43.4%
Gross Profit
$9M
$16M
-43.4%
Operating Income
-$32M
-$16M
-105.2%
Net Income
-$32M
-$16M
-105.6%
← FY 2022
All Quarters
Q2 2022 →